Indian pharma firms may yet survive Trump's 200% tariff bombshell

US President Donald Trump's latest tariff announcement on imported generic medicines has sparked fresh concerns about the future of Indian pharmaceutical exports to the United States. Under the plan, generic drugs entering the US would continue to face a zero tariff for two years, after which the levy would rise to 100% for a year and then 200% thereafter.

The United States imported $213 billion worth of pharmaceutical products in 2025, including $94.1 billion of finished medicines sold in retail packs—the category that includes generic medicines, as per a GTRI report. India has the most at stake among generic drug exporters. It exported $25.8 billion of pharmaceuticals worldwide in 2025, of which $9.7 billion, or 37.7%, went to the US, making America India's largest pharmaceutical export market. Indian companies supply 47% of all generic prescriptions dispensed in the US, making India the country's largest source of affordable generic medicines.

Also Read: Trump announces new generic drugs tariff plan


The huge tariffs appear too heavy for Indian pharma companies which may either be forced to shift manufacturing to America at great business risk or lose out. Yet, the economics of generics manufacturing and the shape of supply chains suggest Indian pharma companies may not ultimately be hurt by these bombshell tariffs as much as may be feared at this stage.

Motilal Oswal Financial Services argues that the economics of the generic drug business make such a transition far more difficult than it sounds. A closer examination of the industry suggests the eventual impact on Indian pharmaceutical companies could be much smaller than the 200% tariff number indicates.

Trump tariffs on generics: The motive and the messaging

Trump has made this move as part of a broader effort to bring pharmaceutical manufacturing back to the US. If imported medicines become prohibitively expensive because of tariffs, companies will be forced to establish factories in America. But the announcement also needs to be viewed through a political lens. Drug prices have long been one of Trump's preferred issues when speaking to voters. Promising to lower medicine costs and reduce America's dependence on foreign manufacturing resonates strongly with large sections of the electorate, particularly older Americans who are among the biggest consumers of prescription drugs.

Also Read: What Trump tariffs on generics mean for Indian pharma sector

That creates pressure on any administration to be seen taking visible and hard action. The unusually long phase-in period built into the tariff proposal allows Trump to project a tough stance on pharmaceutical imports today while postponing the difficult economic consequences of the policy. Whether the measure ultimately succeeds in reshoring large volumes of generic drug production is a separate question.

The question is not whether Indian companies can build plants in the US. Some already have a manufacturing presence there. The real question is whether large volumes of low-cost generic medicines can be produced in America at a price that makes economic sense. That is where the reshoring argument begins to weaken.

The cost advantage for Indian pharma remains enormous

The biggest challenge for any reshoring effort is the cost differential between India and the United States. Indian manufacturers enjoy a structural manufacturing advantage that industry experts often estimate at 40-60%. That advantage is the reason why so many global pharmaceutical companies have relied on Indian production for years. Generic medicines are highly competitive products where buyers constantly push prices lower. Even relatively small increases in manufacturing costs can significantly affect profitability.

Also Read: Trump’s 100% generic drug duty threatens US low-cost supply


If tariffs eventually apply to all imported generic medicines, they will not target India alone. Every overseas supplier to the US market will face the same challenge. As a result, the competitive position of Indian companies relative to other international manufacturers may not change dramatically. In many cases, importing from India could remain economically attractive even after factoring in higher costs because building and operating equivalent capacity in the US is itself extremely expensive.

Why new US factories are not an immediate solution

Another important aspect of the tariff proposal is the time required to create alternative manufacturing capacity. Drug manufacturing is not like assembling consumer products. Building a pharmaceutical facility is only the first step. Once construction is complete, the plant must undergo regulatory inspections. Individual products manufactured at the facility must also go through approval processes before they can be sold.

This means that even if companies decided today to establish new US facilities, meaningful competition to existing Indian production would take years to emerge. The proposed tariff timeline itself appears to acknowledge this reality by providing a two-year window before any duties come into effect. If reshoring were genuinely straightforward, there would be little reason to wait two years before imposing tariffs. The structure of the proposal itself reflects the reality that pharmaceutical supply chains cannot be relocated overnight.

The generic drug market runs on thin margins

The economics of generic medicines create another complication for any reshoring strategy. Generic drugs account for roughly 90% of prescriptions dispensed in the US. Yet they represent only a fraction of overall drug spending because prices are already extremely low. Manufacturers often compete aggressively for market share, leaving limited room for absorbing major cost increases.

This is precisely why tariff threats alone may not trigger a wholesale migration of generic drug manufacturing into America. Higher production costs ultimately have to be absorbed somewhere. Either prices rise, margins shrink or certain products become less attractive to manufacture.

That presents a political challenge as well. Trump wants to be seen as lowering drug costs for American consumers. But if generic manufacturers face substantially higher costs because production shifts to the US, those costs could eventually find their way into the healthcare system. The administration therefore faces the difficult task of encouraging domestic production without undermining one of its central political objectives of keeping medicines affordable. For many commodity generic medicines, the numbers simply do not appear to support large-scale domestic production in the US.

What Motilal Oswal says about Trump generic drug tariffs

Tushar Manudhane, Senior Vice President and Institutional Research Analyst, Healthcare, at Motilal Oswal Financial Services, argues that the practical impact on Indian companies could be limited. Manudhane says multiple Indian companies have subsidiaries in US and there is considerable difference in the pricing at which goods are transferred to US market and then subsequently sold in US market. The tariff is presumably at pricing at which it enters US market. Secondly, he says, 90% of generic prescription is imported by US, effectively increasing the tariff for everyone (as and when it happens) supplying to US market and it is not India specific. Also, the concept of outsourcing to countries like India is based on 40-60% lower cost of manufacturing in India compared to that in US. Tariff implementation would still fall short and would not lower this advantage of low cost manufacturing from India.

Even if the manufacturing plant is set up (which itself takes 2 years atleast), Manudhane says it would be required to undergo plant inspection and subsequent product approval cycle of at least 12-15 months, further prolonging any competition to kick in.

Above factors questions the economic viability of setting up a manufacturing plant in US for generics. As per Manudhane, this effectively would mean minimal impact on indian pharma companies supplying medicines to US market.

Trump tariffs on generic medicines: What GTRI says

According to the Global Trade Research Initiative (GTRI), Trump's proposed tariffs could affect India's largest pharmaceutical export market, but the impact is unlikely to be uniform across products or companies. The GTRI points out that many Indian generic medicines are sold in the US at prices that are seven to ten times lower than their branded equivalents.

As a result, even if a 100% tariff is eventually imposed, many Indian generics could still remain cheaper than branded alternatives, meaning a significant portion of the additional cost may ultimately be borne by US healthcare providers, insurers and patients rather than immediately displacing Indian exports from the market. The think tank believes the greatest pressure would fall on higher-value generic formulations and branded generics, where manufacturing in the United States could become commercially viable.

The GTRI also notes that several major Indian pharmaceutical companies already have an established manufacturing presence in America. It cites FDA-approved US manufacturing facilities operated by Sun Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Cipla and Dr. Reddy's Laboratories. According to the GTRI, Cipla is expanding production capacity at its facilities in Massachusetts and New York, while Dr. Reddy's has indicated that it would be willing to increase US manufacturing if the economics justify such a move. Sun Pharma, however, has publicly stated that its current US manufacturing footprint is adequate and that it has no immediate plans for further expansion. At the same time, the GTRI argues that large-scale reshoring of generic drug production will be far from straightforward because the generic medicines business operates on extremely thin margins and depends heavily on global supply chains, particularly for active pharmaceutical ingredients sourced from India and China.

The think tank says creating a fully domestic US pharmaceutical supply chain would require substantial investment and would almost certainly raise medicine prices. The GTRI further notes that the proposal's two-year implementation window introduces significant uncertainty because US political and legal developments could still alter, delay or even overturn the policy before it takes effect.

Indian generic medicine's entrenched position in the US market

The US healthcare system's dependence on imported generics also works in India's favour. Indian companies supply nearly half of generic medicines consumed in the US. Over the years, firms such as Sun Pharma, Dr. Reddy's Laboratories, Lupin, Aurobindo Pharma, Cipla and Zydus have built deep relationships with distributors, pharmacy chains and healthcare providers. They have also invested heavily in US regulatory compliance and product approvals.

Replacing this ecosystem would require not only new factories but also new supply chains, new regulatory clearances and new manufacturing expertise. That process could take several years even under an aggressive policy push. As a result, any effort to dramatically reduce dependence on imported generics is likely to be slower and more complicated than Trump's rhetoric suggests.

Why investors may not panic about Trump generic drug tariffs

The market's assessment of the proposal will ultimately depend on whether investors believe the tariffs will ever reach the announced levels and whether they can be implemented without disrupting drug supplies. The two-year tariff-free period gives companies time to adapt. It also creates room for policy negotiations, industry lobbying and potential revisions. The pharmaceutical industry has historically been effective at highlighting the risks of policies that could lead to shortages or higher healthcare costs. Then there is the impending trade deal which might offer carve-outs for India in case of pharma tariffs.

More importantly, the core economics that made India a global pharmaceutical manufacturing hub remains intact. The cost advantage is substantial. Regulatory barriers are high. New capacity takes years to build and approve. None of those realities change because of a tariff announcement.

It is entirely possible that the announcement delivers immediate political benefits by demonstrating action on an issue that matters to voters. The longer-term effectiveness of the policy, however, will ultimately be judged by whether it meaningfully alters manufacturing economics. At the moment, there is little evidence that it can do that to a big extent.

Trump generic medicine tariffs and the bottom line

Trump's proposal is clearly designed to encourage domestic pharmaceutical manufacturing and reinforce his longstanding message on drug affordability. Yet the generic drug industry operates under economic constraints that make rapid reshoring difficult. India's manufacturing cost advantage remains significant. The US continues to rely heavily on imported generics. Building replacement capacity would require years of investment and regulatory approvals.

For that reason, the announcement may prove to be more consequential as a political signal and negotiating tool than as a catalyst for a grand tectonic shift in global generics supply chains as Trump desires. Some Indian companies may enlarge their US footprints or some may create US capacities anew possibly by buying smaller US companies or onshore manufacturing of only some types of generics but a giant disruption may not happen after the two-year period ends.

While the policy introduces uncertainty, the underlying structure of the generic drug market suggests that Indian pharmaceutical companies are unlikely to face the kind of disruption implied by the mega headline tariff figures.